March Biosciences

March Biosciences is a clinical-stage biotechnology company focused on developing innovative chimeric antigen receptor T-cell (CAR-T) therapies for challenging cancers. The company's lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in development for the treatment of relapsed and refractory CD5-positive T-cell lymphomas and leukemias. MB-105 is engineered to overcome T-cell fratricide while maintaining potency against CD5-positive tumor cells. This approach aims to preserve healthy T-cells while effectively targeting malignant ones, addressing a key challenge in T-cell cancer treatment. In an ongoing Phase 1 trial, MB-105 has demonstrated a favorable safety profile and encouraging early efficacy in patients with relapsed T-cell lymphoma and T-cell acute lymphoblastic leukemia. March Biosciences plans to initiate a Phase 2 clinical trial of MB-105 in early 2025.

The company was launched as a spinout from the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital. In October 2024, March Biosciences closed a USD 28.4 million Series A financing round, bringing its total funding to over USD 51 million. The company has also received substantial non-dilutive funding, including a USD 13.4 million award from the Cancer Prevention and Research Institute of Texas (CPRIT) in November 2023.